# Medpace

> Medpace is a Cincinnati-based, founder-led contract research organization that runs Phase I-IV clinical development programs for biotechnology, pharmaceutical and medical-device sponsors. Its proposition is an integrated one: clinical operations, therapeutic physicians, regulatory guidance, data and biostatistics, safety, central and bioanalytical laboratories, imaging and cardiac core labs, logistics, and proprietary trial technology sit within one full-service model. That structure is aimed especially at small and midsize biotech companies that need the capabilities of a large development organization without building one in-house.

- **Founded:** 1992
- **Headquarters:** Cincinnati, United States
- **Founders:** August J. Troendle, MD (Founder, Chairman and CEO)
- **Team size:** Approximately 6,500 employees across 46 countries as of June 30, 2026
- **Products:** Full-service Phase I-IV clinical development, ClinTrak, IntelliPACE, Central laboratories, Bioanalytical laboratory
- **Notable:** Completed its Nasdaq IPO in August 2016 under the ticker MEDP., Grew fiscal 2025 revenue 20.0% to $2.5302 billion., Reached approximately 6,500 employees across 46 countries by June 2026.

## Products & services

- **Full-service Phase I-IV clinical development** — Study start-up, project management, monitoring, site and patient services, packaging and supplies, medical affairs, safety, regulatory work, medical writing, quality assurance, biostatistics and data management.
- **ClinTrak** — An in-house, customizable clinical trial platform combining CTMS, IRT, EDC, laboratory, imaging and electronic patient-reported outcome modules with cross-study dashboards.
- **IntelliPACE** — A data-informed feasibility, country, site and patient recruitment planning system drawing on internal performance history and external research datasets.
- **Central laboratories** — Wholly owned global labs providing safety testing, biomarkers, microbiology, biorepository services and trial-sample logistics on standardized platforms.
- **Bioanalytical laboratory** — Small- and large-molecule bioanalysis, method development and validation, pharmacokinetic and toxicokinetic studies, biomarker and immunogenicity assays.
- **Imaging and cardiovascular core labs** — Centralized imaging analysis, image quantification, cardiac safety, ECG review and wearable biosensor services for trials.
- **Clinical Pharmacology Unit** — An 85-bed Cincinnati Phase I facility with four inpatient units, pharmacy, physician oversight and direct access to Medpace laboratories and specialists.
- **Medical device and diagnostics development** — Clinical and regulatory support for medical-device and diagnostic programs, integrated with the wider CRO service stack.

## Achievements

- Completed its Nasdaq IPO in August 2016 under the ticker MEDP.
- Grew fiscal 2025 revenue 20.0% to $2.5302 billion.
- Reached approximately 6,500 employees across 46 countries by June 2026.
- Won the Society for Clinical Research Sites' 2025 CRO Eagle Award, based on voting by nearly 2,000 research sites.
- Received a 2025 WCG Pinnacle Award for professionalism and communication in site relationships.
- Built a network of wholly owned central laboratories serving studies across six continents.
- Expanded the Leuven, Belgium logistics hub to more than 4,000 square meters in 2025.

## Latest updates

- **2026-07** — Reported second-quarter revenue of $707.3 million, up 17.2% year over year, and net new business awards of $795.7 million; headcount reached about 6,500.
- **2026-07** — Participated in the third Alport Research Hub Symposium in London, extending its rare-nephrology engagement.
- **2026-06** — Published new laboratory and therapeutic expertise features covering molecular innovation, ophthalmic gene therapy and diabetes trials.
- **2025-10** — Named the 2025 CRO Eagle Award recipient by the Society for Clinical Research Sites.
- **2025-06** — Expanded its Leuven clinical-trial logistics hub to more than 4,000 square meters, with capacity for more than 300,000 collection kits.
- **2025-04** — Expanded microbiology capabilities at central laboratories in Cincinnati and Shanghai.
- **2025** — More than doubled the space of its Shanghai central laboratory to 1,945 square meters.

## Links

- Website: https://www.medpace.com/
- LinkedIn: https://www.linkedin.com/company/medpace
- Twitter/X: https://twitter.com/WorkatMedpace
- Facebook: https://facebook.com/MedpaceInc/

---

Profile page: https://yespress.io/medpace
Published by YesPress — https://yespress.io
Last updated: 2026-08-11